129 related articles for article (PubMed ID: 35373021)
1. Multidisciplinary Team versus a "Phosphate-Counting" App for Serum Phosphate Control: A Randomized Controlled Trial.
Farfan-Ruiz AC; Czikk D; Leidecker J; Ramsay T; McCormick B; Wilson K; Zimmerman D
Kidney360; 2021 Feb; 2(2):290-297. PubMed ID: 35373021
[TBL] [Abstract][Full Text] [Related]
2. A Pilot Study of OkKidney, a Phosphate Counting Application in Patients on Peritoneal Dialysis.
Imtiaz R; Atkinson K; Guerinet J; Wilson K; Leidecker J; Zimmerman D
Perit Dial Int; 2017; 37(6):613-618. PubMed ID: 28970367
[TBL] [Abstract][Full Text] [Related]
3. Meal phosphate variability does not support fixed dose phosphate binder schedules for patients treated with peritoneal dialysis: a prospective cohort study.
Leung S; McCormick B; Wagner J; Biyani M; Lavoie S; Imtiaz R; Zimmerman D
BMC Nephrol; 2015 Dec; 16():205. PubMed ID: 26645271
[TBL] [Abstract][Full Text] [Related]
4. Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients.
Imtiaz R; Hawken S; McCormick BB; Leung S; Hiremath S; Zimmerman DL
Nutrients; 2017 Feb; 9(2):. PubMed ID: 28218647
[TBL] [Abstract][Full Text] [Related]
5. Multidisciplinary education approach to optimize phosphate control among hemodialysis patients.
Chan MW; Cheah HM; Mohd Padzil MB
Int J Clin Pharm; 2019 Oct; 41(5):1282-1289. PubMed ID: 31302884
[TBL] [Abstract][Full Text] [Related]
6. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
Pergola PE; Rosenbaum DP; Yang Y; Chertow GM
J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811
[TBL] [Abstract][Full Text] [Related]
8. Improving diet recipe and cooking methods attenuates hyperphosphatemia in patients undergoing peritoneal dialysis.
Jiang N; Fang W; Gu AP; Yuan JZ; Yang XX; Lin AW; Ni ZH; Qian JQ
Nutr Metab Cardiovasc Dis; 2015 Sep; 25(9):846-852. PubMed ID: 26141941
[TBL] [Abstract][Full Text] [Related]
9. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
10. Design and Rationale of HiLo: A Pragmatic, Randomized Trial of Phosphate Management for Patients Receiving Maintenance Hemodialysis.
Edmonston DL; Isakova T; Dember LM; Brunelli S; Young A; Brosch R; Beddhu S; Chakraborty H; Wolf M
Am J Kidney Dis; 2021 Jun; 77(6):920-930.e1. PubMed ID: 33279558
[TBL] [Abstract][Full Text] [Related]
11. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM).
Block GA; Bleyer AJ; Silva AL; Weiner DE; Lynn RI; Yang Y; Rosenbaum DP; Chertow GM
Kidney360; 2021 Oct; 2(10):1600-1610. PubMed ID: 35372979
[TBL] [Abstract][Full Text] [Related]
13. Calcium-enriched bread for treatment of uremic hyperphosphatemia.
Babarykin D; Adamsone I; Amerika D; Spudass A; Moisejev V; Berzina N; Michule L; Rozental R
J Ren Nutr; 2004 Jul; 14(3):149-56. PubMed ID: 15232793
[TBL] [Abstract][Full Text] [Related]
14. Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders.
Sherman RA
Am J Kidney Dis; 2016 Feb; 67(2):182-6. PubMed ID: 26508681
[TBL] [Abstract][Full Text] [Related]
15. Interventional study to improve adherence to phosphate binder treatment in dialysis patients.
Hjemås BJ; Bøvre K; Mathiesen L; Lindstrøm JC; Bjerknes K
BMC Nephrol; 2019 May; 20(1):178. PubMed ID: 31101020
[TBL] [Abstract][Full Text] [Related]
16. Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence.
Coyne DW; Sprague SM; Vervloet M; Ramos R; Kalantar-Zadeh K
J Nephrol; 2022 Apr; 35(3):875-888. PubMed ID: 35138627
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
Joy MS; Finn WF;
Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
[TBL] [Abstract][Full Text] [Related]
18. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
Finn WF;
Clin Nephrol; 2006 Mar; 65(3):191-202. PubMed ID: 16550750
[TBL] [Abstract][Full Text] [Related]
19. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
Weinreich T; Ritz E; Passlick-Deetjen J
Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
[TBL] [Abstract][Full Text] [Related]
20. Low prevalence of hyperphosphatemia independent of residual renal function in peritoneal dialysis patients.
Dong J; Wang H; Wang M
J Ren Nutr; 2007 Nov; 17(6):389-96. PubMed ID: 17971311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]